Related Experiment Video
Updated: Aug 5, 2026
Assessing Cortical Cerebral Microinfarcts on High Resolution MR Images
Published on: November 20, 2015
Diagnostic Accuracy of the Boston Criteria v2.0 in Memory Clinic Patients: An MRI-Neuropathology Validation Study
Emerson Kropp1, Maria Varkanitsa1, Thor D Stein2
1Center for Brain Recovery, Boston University, MA.
Insights
The Boston Criteria v2.0 for diagnosing cerebral amyloid angiopathy (CAA) in memory clinics showed modest accuracy, with a slight increase in sensitivity but no significant overall improvement over v1.5. Further research is needed for better in vivo diagnosis.
Area of Science:
- Neurology
- Neuroimaging
- Pathology
Background:
- Cerebral amyloid angiopathy (CAA) is a common cause of cognitive decline in older adults.
- Current diagnostic criteria (Boston Criteria) were developed mainly for patients with hemorrhage, limiting their use in memory clinics.
- Updated Boston Criteria v2.0 include non-hemorrhagic MRI markers to enhance detection.
Purpose of the Study:
- To evaluate the diagnostic accuracy of Boston Criteria v1.5 and v2.0 for probable cerebral amyloid angiopathy (CAA).
- To compare the performance of the two criteria versions in memory clinic patients against neuropathological confirmation.
Main Methods:
- Retrospective diagnostic accuracy study using data from the Alzheimer's Disease Neuroimaging Initiative and National Alzheimer's Coordinating Center.
- Participants were classified using Boston Criteria v1.5 and v2.0, with moderate-to-severe neuropathologic CAA as the reference standard.
- Diagnostic performance metrics including sensitivity, specificity, and AUC were calculated and compared.
Main Results:
- Boston Criteria v1.5 showed sensitivity of 32% and AUC 0.59 for moderate-to-severe CAA.
- Boston Criteria v2.0 showed sensitivity of 43% and AUC 0.63, indicating a numerical increase.
- No significant differences in overall performance measures were observed between the two criteria versions.
Conclusions:
- Both Boston Criteria versions demonstrate modest diagnostic performance for CAA in memory clinic patients.
- Boston Criteria v2.0 offers a potential shift towards higher sensitivity but not a clear overall accuracy gain.
- Improved in vivo diagnosis of CAA in non-hemorrhagic populations requires additional biomarkers.
Background And Objectives:
Cerebral amyloid angiopathy (CAA) is common in older adults and frequently contributes to cognitive impairment and dementia. Existing in vivo diagnostic criteria for CAA (Boston Criteria) were developed primarily in patients with intracerebral hemorrhage, and their performance in memory clinic populations remains uncertain. The updated Boston Criteria v2.0 incorporate nonhemorrhagic MRI markers intended to improve case detection. We evaluated the diagnostic accuracy of the Boston Criteria v1.5 and v2.0 against neuropathologically confirmed CAA in memory clinic patients.
Methods:
We performed a retrospective diagnostic accuracy study of participants from the Alzheimer's Disease Neuroimaging Initiative and National Alzheimer's Coordinating Center, selected based on availability of required brain MRI and autopsy-based neuropathology data. Patients were classified as no, possible, or probable CAA according to the Boston Criteria v1.5 and v2.0. The primary reference standard was moderate-to-severe neuropathologic CAA; analyses using any neuropathologic CAA were secondary/exploratory. Diagnostic performance was assessed using sensitivity, specificity, predictive values, likelihood ratios, F1 scores, accuracy, and area under the (receiver-operating characteristic) curve (AUC), with formal comparisons between criteria versions.
Results:
Eighty patients were included (mean age: 81 years, interquartile range 74-86 years; 36.2% female, ∼80% with dementia and Alzheimer disease). Using moderate-to-severe CAA as the neuropathologic reference standard, probable CAA by Boston Criteria v1.5 had a sensitivity of 32% (95% CI 15%-50%), specificity 87% (77%-95%), and AUC 0.59 (0.49-0.69). Using the Boston Criteria v2.0, the corresponding values were 43% (25%-62%), 83% (72%-92%), and 0.63 (0.52-0.74), respectively. No overall performance measures were significantly different between the criteria versions. Secondary analyses using any neuropathologic CAA showed similar patterns.
Discussion:
In memory clinic patients, both Boston Criteria versions showed only modest overall diagnostic performance against neuropathology. Compared with v1.5, Boston Criteria v2.0 showed a numerical shift toward greater sensitivity at the expense of specificity but no clear overall gain in accuracy. These findings support cautious, context-dependent interpretation of MRI-based CAA criteria in memory clinic settings and highlight the need for additional biomarkers to improve in vivo diagnosis in nonhemorrhagic populations.
Classification Of Evidence:
This study provides Class II evidence that, in memory clinic populations, Boston Criteria v2.0 show a trade-off between sensitivity and specificity for probable CAA diagnosis, with only modest overall diagnostic accuracy for identifying moderate-to-severe neuropathologically defined CAA.
